Praxis precision medicines prices public offering of common stock

Cambridge, mass., may 13, 2021 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (cns) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share. the gross proceeds to praxis from the offering are expected to be approximately $91.25 million, before deducting the underwriting discounts and commissions and other offering expenses. praxis has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.
PRAX Ratings Summary
PRAX Quant Ranking